Compare Moderna, Inc. (MRNA) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Oatly Group AB - ADR — how do they compare? Moderna, Inc. trades at $63.68 (market cap $24.18B), while Oatly Group AB - ADR trades at $12.93 (market cap $415.98M). The key difference: Moderna, Inc. is far larger — about 58.1× Oatly Group AB - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| MRNA | OTLY | |
|---|---|---|
Market Cap | $24.18B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $81.80 | $18.54 |
52-Week Low | $22.36 | $8.03 |
Enterprise Value | $20.33B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Oatly (OTLY) trades at $13.23, up 0.84% today, with a bullish technical signal supported by moving averages and RSI. The company reported Q2 2026 revenue of $240.1 million, beating expectations, and raised its full-year outlook. However, it remains unprofitable with a net income margin of -13.81% and negative cash flow. Analyst sentiment is mixed with 44% buy ratings, 50% hold, and 6% sell.
Outlook hinges on revenue growth and margin improvements, but risks include high debt, persistent cash burn, and delayed profitability. The stock offers speculative upside if operational turnaround accelerates, yet investors face significant financial stability concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
